Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOX4 | Q9NPH5 | 18/20 | 0.50 |
| ▸ | CYBB | P04839 | 3/20 | 0.42 |
| ▸ | NOX1 | Q9Y5S8 | 3/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.39 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.38 |
| ▸ | NOX5 | Q96PH1 | 2/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2846433 | 0.80 | NOX4 (0.56) | NOX4CYBBNOX1CYP3A4 | |
| SCHEMBL1723241 | 0.76 | NOX4 (0.53) | NOX4CYBBNOX1CYP3A4 | |
| SCHEMBL1302005 | 0.74 | NOX4 (0.56) | NOX4CYBBNOX1CYP3A4 | |
| SCHEMBL1302126 | 0.70 | NOX4 (0.60) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL1302490 | 0.70 | NOX4 (0.55) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL1723239 | 0.67 | NOX4 (0.38) | NOX4CYBBNOX1CYP3A4NOTUM | |
| SCHEMBL1303017 | 0.67 | NOX4 (1.00) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL1302427 | 0.66 | NOX4 (0.58) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL12107202 | 0.65 | NOX4 (0.77) | NOX4CYBBNOX1CYP3A4NOX5 | |
| SCHEMBL7070074 | 0.65 | ALDH1A1 (0.69) | NOX4NOTUM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9974791-B2 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-05-22 | — | — | US | claimed |
| EP-2860179-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-03-14 | — | — | EP | claimed |
| EP-2344492-B1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2014-10-29 | — | — | EP | claimed |
| EP-2344492-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GenKyoTex SA (CH) | 2011-07-20 | — | — | EP | claimed |
| EP-2860179-B1 | Pyrazolo pyridine derivatives as NADPH oxidase inhibitors | GENKYOTEX SUISSE SA (CH) | 2018-03-14 | — | — | EP | disclosed |
| US-20110269757-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | GENKYOTEX SA (CH) | 2011-11-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110269757-A1 | PYRAZOLO PYRIDINE DERIVATIVES AS NADPH OXIDASE INHIBITORS | NOX1, NOX4, CYBB | NOX4 2/4885CYBB 3/4885NOX1 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.